Show simple item record

dc.contributor.authorRasche, L
dc.contributor.authorAngtuaco, E
dc.contributor.authorMcDonald, JE
dc.contributor.authorBuros, A
dc.contributor.authorStein, C
dc.contributor.authorPawlyn, C
dc.contributor.authorThanendrarajan, S
dc.contributor.authorSchinke, C
dc.contributor.authorSamant, R
dc.contributor.authorYaccoby, S
dc.contributor.authorWalker, BA
dc.contributor.authorEpstein, J
dc.contributor.authorZangari, M
dc.contributor.authorvan Rhee, F
dc.contributor.authorMeissner, T
dc.contributor.authorGoldschmidt, H
dc.contributor.authorHemminki, K
dc.contributor.authorHoulston, R
dc.contributor.authorBarlogie, B
dc.contributor.authorDavies, FE
dc.contributor.authorMorgan, GJ
dc.contributor.authorWeinhold, N
dc.date.accessioned2021-01-12T09:54:08Z
dc.date.issued2017-07
dc.identifier.citationBlood, 2017, 130 (1), pp. 30 - 34
dc.identifier.issn0006-4971
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/4274
dc.identifier.eissn1528-0020
dc.identifier.doi10.1182/blood-2017-03-774422
dc.description.abstract18 F-Fluorodeoxyglucose (FDG)-positron emission tomography (PET) and diffusion-weighted magnetic resonance imaging with background signal suppression (DWIBS) are 2 powerful functional imaging modalities in the evaluation of malignant plasma cell (PC) disease multiple myeloma (MM). Preliminary observations have suggested that MM patients with extensive disease according to DWIBS may be reported as being disease-free on FDG-PET ("PET false-negative"). The aim of this study was to describe the proportion of PET false-negativity in a representative set of 227 newly diagnosed MM patients with simultaneous assessment of FDG-PET and DWIBS, and to identify tumor-intrinsic features associated with this pattern. We found the incidence of PET false-negativity to be 11%. Neither tumor load-associated parameters, such as degree of bone marrow PC infiltration, nor the PC proliferation rate were associated with this subset. However, the gene coding for hexokinase-2, which catalyzes the first step of glycolysis, was significantly lower expressed in PET false-negative cases (5.3-fold change, P < .001) which provides a mechanistic explanation for this feature. In conclusion, we demonstrate a relevant number of patients with FDG-PET false-negative MM and a strong association between hexokinase-2 expression and this negativity: a finding which may also be relevant for clinical imaging of other hematological cancers.
dc.formatPrint-Electronic
dc.format.extent30 - 34
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://www.rioxx.net/licenses/all-rights-reserved
dc.subjectHumans
dc.subjectMultiple Myeloma
dc.subjectHexokinase
dc.subjectFluorodeoxyglucose F18
dc.subjectNeoplasm Proteins
dc.subjectFalse Positive Reactions
dc.subjectPositron-Emission Tomography
dc.subjectGene Expression Regulation, Enzymologic
dc.subjectGene Expression Regulation, Neoplastic
dc.subjectFemale
dc.subjectMale
dc.titleLow expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myeloma.
dc.typeJournal Article
dcterms.dateAccepted2017-04-13
rioxxterms.versionofrecord10.1182/blood-2017-03-774422
rioxxterms.licenseref.urihttps://www.rioxx.net/licenses/all-rights-reserved
rioxxterms.licenseref.startdate2017-07
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfBlood
pubs.issue1
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Myeloma Biology and Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Genetics and Epidemiology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Genetics and Epidemiology/Cancer Genomics
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Myeloma Biology and Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Genetics and Epidemiology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Genetics and Epidemiology/Cancer Genomics
pubs.publication-statusPublished
pubs.volume130
pubs.embargo.termsNot known
icr.researchteamMyeloma Biology and Therapeuticsen_US
icr.researchteamCancer Genomicsen_US
dc.contributor.icrauthorPawlyn, Charlotteen
dc.contributor.icrauthorHoulston, Richarden


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record